BioInvent International AB appointed Michael Oredsson new CEO and will take up the post on August 19, 2013.

The company reported earnings results for the first half ended June 30, 2013. For the half year, the company reported net sales amounted to SEK 24 million against SEK 21 million a year ago. Loss after tax for the period was SEK 24 million against SEK 129 million a year ago. Loss per share, before and after dilution was SEK 0.32 against SEK 1.84 a year ago. Cash flow used in current operations and investment activities was SEK 60 million against SEK 84 million a year ago.